BioCryst Pharmaceuticals Inc. (BCRX)
NASDAQ · Healthcare
BioCryst Pharmaceuticals Inc. EBITDA 2009–2025
BioCryst Pharmaceuticals Inc. annual/quarterly ebitda history and growth rate from 2010 to 2025. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- BioCryst Pharmaceuticals Inc. ebitda for the quarter ending March 31, 2025 was 21.6 M, a 252.01% decrease year-over-year.
- BioCryst Pharmaceuticals Inc. ebitda for the twelve months ending March 31, 2025 was -70.3 M, a 50.91% decrease year-over-year.
- BioCryst Pharmaceuticals Inc. annual ebitda for 2025 was 342.4 M, a 26497.69% decrease from 2024.
- BioCryst Pharmaceuticals Inc. annual ebitda for 2024 was -1.3 M, a 98.73% decrease from 2023.
- BioCryst Pharmaceuticals Inc. annual ebitda for 2023 was -102.1 M, a 30.57% decrease from 2022.
- BioCryst Pharmaceuticals Inc. annual ebitda for 2022 was -147.0 M.
EBITDA
TRAILING 12 MONTHS · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
BioCryst Pharmaceuticals Inc. EBITDA — FAQ
BioCryst Pharmaceuticals Inc. (BCRX) ebitda over the last 17 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see BCRX's ebitda history?
The chart and table above show BioCryst Pharmaceuticals Inc.'s ebitda by year and by quarter, including the growth rate.